Abstract: Compositions and methods are provided that are effective in treating skin hyperproliferative disorders. These include a topical pharmaceutical preparation that includes a compound that has two or more of a SRC-kinase inhibiting activity, a tubulin polymerization inhibiting activity, an activity that arrests the cell cycle at G2/M, and an activity that induces apoptosis. The compound KX01 is provided as an example of such a compound. The topical pharmaceutical preparation further includes a vitamin D derivative or a retinoid, where the combination provides a synergistic effect. Use of the topical pharmaceutical preparation can be combined with exposure to blue, UVA, or UVB light, which provides a synergistic effect.

Abstract: The present disclosure relates to compounds of Formula (IA) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for the treatment of disorders in which P-glycoprotein and/or cytochrome P450 (e.g. CYP3A4) is modulated (e.g., cancers which have developed multi-drug resistance).

Abstract: The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for the treatment of disorders in which expression of P-glycoprotein and/or cytochrome P450 (e.g., CYP3A4) is modulated (e.g., cancers which have developed multi-drug resistance).

Abstract: The present disclosure relates to compounds of Formula (IA) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for the treatment of disorders in which P-glycoprotein and/or cytochrome P450 (e.g. CYP3A4) is modulated (e.g., cancers which have developed multi-drug resistance).

Abstract: Compositions and methods are provided that are effective in treating skin hyperproliferative disorders. These include a topical pharmaceutical preparation that includes a compound that has two or more of a SRC-kinase inhibiting activity, a tubulin polymerization inhibiting activity, an activity that arrests the cell cycle at G2/M, and an activity that induces apoptosis. The compound KX01 is provided as an example of such a compound. The topical pharmaceutical preparation further includes a vitamin D derivative or a retinoid, where the combination provides a synergistic effect. Use of the topical pharmaceutical preparation can be combined with exposure to blue, UVA, or UVB light, which provides a synergistic effect.